OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
186,900
+5,100 (2.81%)
At close: Mar 20, 2026
Market Cap3.77T +373.7%
Revenue (ttm)14.67B +158.3%
Net Income-15.74B
EPS-800.00
Shares Out20.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume740,615
Average Volume493,958
Open181,800
Previous Close181,800
Day's Range179,000 - 189,600
52-Week Range34,500 - 217,000
Beta0.61
RSI56.82
Earnings DateMar 27, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2025, OliX Pharmaceuticals's revenue was 14.67 billion, an increase of 158.35% compared to the previous year's 5.68 billion. Losses were -15.74 billion, -61.28% less than in 2024.

Financial Statements